*Disseminated on Behalf of Cardiol Therapeutics Inc.
Market Crux Announces Coverage On Cardiol Therapeutics Inc. (NASDAQ: CRDL)
See Why We'll Have All Eyes On (CRDL) First Thing Tomorrow Morning
—Tuesday, December 2, 2025
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Consider Starting Your Own Research On (CRDL) Before The Bell Rings
Tomorrow Morning [Company Website] | [Corporate Presentation]
December 1, 2025
After-Hours Spotlight | See Why (CRDL) Just Jumped Onto Tuesday's Early Watchlist Dear Reader, Progress in cardiovascular medicine is rapidly reshaping care for inflammatory heart disease, an area where treatment choices remain limited and patient need is high. Work focused on myocarditis and pericarditis is steadily advancing, with early data and active clinical programs pointing toward more meaningful options for people living with these difficult conditions. At the center of this effort is a clinical-stage life sciences company guided by an experienced leadership team that includes former Amgen and Eli Lilly executives and a focused mandate to address critical gaps in cardiac treatment. With multiple initiatives emerging, including those aimed at heart failure, the group's growing footprint across the heal-thcare sector is turning its progress into a key development for observers of innovation in heart care. And with promising advances in its Phase 2 ARCHER trial, strong patent protection securing their competitive position, and several analyst targets suggesting potential triple-digit upside, this under-the-radar Nasdaq profile tops our watchlist Tuesday: *Cardiol Therapeutics Inc. (Nasdaq: CRDL)*
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. And based on several potential catalysts, (Nasdaq: CRDL) takes over Wednesday's watchlist's top spot. Check them out: #1. Advancing Therapies That Target Inflammation In The Heart! #2. Promising Advances In Myocarditis Treatment Strengthen Future Outlook. #3. Cardiol Therapeutics Secures Broad Patent Protection Through Late 2040. #4. Cardiol Therapeutics Announced Phase 2 Results For ARCHER. #5. Multiple Analyst Targets Point To Triple-Digit Potential Upside! But more on those in a second...
Cardiol's Immediate Focus
The company is focused on understanding how inflammation and fibrosis contribute to diseases of the heart and to develop therapies, now in clinical trials for rare cardiac conditions, to target these mechanisms and promote healing. Pericarditis
Pericarditis is the most common pericardial disease, responsible for about 5% of emergency room admissions for chest pain in North America and Western Europe. Recurrent pericarditis is the re-appearance of symptoms after a symptom-free period of at least 4 – 6 weeks following an initial acute episode of pericarditis. Recurrent pericarditis develops in 15–30% of cases, impacting nearly ~38,000 patients annually. Each hospitalization can cost $20k–$30k, creating a significant burden. Patients face sharp chest pain, fatigue, and repeat hospital stays, with rare but serious complications like tamponade and constrictive pericarditis. The only FDA-approved treatment, rilonacept, costs over $270,000 per year. Options remain limited, underscoring the urgent need for new therapies. Cardiol's MAVERIC program for recurrent pericarditis has two parts. The first, a Phase 2 study, is already completed. The second is a pivotal Phase 3 trial currently enrolling patients across approximately 20 sites in the U.S., Canada, and Europe. This global, randomized, double-blind, placebo-controlled study is designed to determine whether CardiolRx™ can prevent disease recurrence in high-risk patients and support regulatory approval.
----- Myocarditis Acute myocarditis is a leading cause of sudden cardiac death in people under 35 years of age.
Myocarditis is when the heart muscle gets inflamed. It can cause chest pain, trouble with how the heart works, and abnormal heart rhythms. In some cases, it can lead to severe heart failure or even sudden death, especially in people under 35. Most often, it's caused by a virus, but it can also come from bacteria, certain medications, mRNA vaccines, or cancer treatments like chemotherapy and immune- based drugs. CardiolRx™ was tested in the ARCHER trial, a Phase 2 study which took place in the U.S., Canada, Brazil, France, and Israel. The goal was to see if the drug is safe, well tolerated, and helps the heart recover in people with acute myocarditis. The full results were just announced!
----- Heart Failure Heart failure affects more than 6.7 million people in the U.S. and associated heal-thcare costs exceed $30Bn annually in the U.S. alone.
Heart failure is when the heart can't pump enough blood and oxygen for the body. This can cause shortness of breath, a fast heartbeat, swelling, low energy, and trouble doing everyday activities. Many people with heart failure end up in the hospital often, and it can greatly affect quality of life. It can be caused by heart attacks, high blood pressure, heart valve problems, heart inflammation (like myocarditis), certain cancer treatments, or inherited conditions. CRD-38 is Cardiol's new subcutaneously administered drug formulation targeting heart failure caused by inflammation. They're doing the prep work needed before starting clinical trials to see if it can become a new treatment option. ----- Product Pipeline
Therapeutic Development - CardiolRx™
CardiolRx™ is an oral, clinical-stage therapy designed to target the underlying inflammation that drives some of the most serious heart conditions. CardiolRx™ attenuates multiple inflammatory signaling pathways, including inhibiting activation of the NLRP3 inflammasome, which is known to play an important role in the inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The drug is made to the highest pharmaceutical standards (cGMP) to ensure purity, consistency, and stability. In clinical trials, CardiolRx™ continues to show a profile that is safe and well tolerated.
These strong safety results helped Cardiol w-in IND authorization from the FDA approvals to conduct Phase 2 and Phase 3 trials in rare heart conditions — recurrent pericarditis and acute myocarditis — giving the company a direct path toward targeting high-value, underserved markets. 
The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis. CardiolRx™ is also eligible for FDA ODD in acute myocarditis and European Medicine Agency orphan medicine designations for recurrent pericarditis and acute myocarditis. Breaking News...
Cardiol Therapeutics Completes $11.4Mn Financing and Extends Cash Runway into Q3 2027
"As recruitment in our pivotal Phase III MAVERIC trial gains momentum, with several prominent centers across the U.S. now enrolling patients, we are pleased to have secured a direct in-vest-ment of $11.4Mn to strengthen our balance sheet and accelerate the development of our novel heart failure drug, CRD-38, based on the recently reported findings from our ARCHER trial," said David Elsley, President and CEO of Cardiol Therapeutics.
Grab Sources And More: CRDL Website. CRDL Presentation.
----- And as I mentioned earlier, (Nasdaq: CRDL) has several potential catalysts to consider. Take a look: #1. CRDL Potential Catalyst - Advancing Therapies that Target Inflammation in the Heart!
Cardiol Therapeutics is developing CardiolRx™, an oral canna-bidiol therapy designed to treat heart conditions like recurrent pericarditis and acute myocarditis by targeting inflammation. Promising Phase 2 results for CardiolRx™ showed improvements in cardiac MRI markers and significant LV mass reduction, with ongoing Phase 3 MAVERIC trials further evaluating its potential in preventing pericarditis recurrence. The company is also advancing CRD-38, a novel subcutaneous drug for heart failure, addressing a critical global health issue. These therapies demonstrate strong clinical promise and excellent safety profiles.
----- #2. CRDL Potential Catalyst - Promising Advances In Myocarditis Treatment Strengthen Cardiol Therapeutics' Outlook.
Over the weekend, Cardiol Therapeutics announced positive results from its Phase 2 ARCHER trial at the European Society of Cardiology's Myocardial & Pericardial Diseases meeting. ARCHER data was presented by Dr. Leslie Cooper from Mayo Clinic that showed CardiolRx™ improved extracellular volume and significantly reduced left ventricular mass, key markers of cardiac recovery. These findings reinforce Cardiol's anti-inflammatory approach to treating acute myocarditis and support broader applications in chronic heart failure. Following the presentation, company management hosted a webcast highlighting the trial's success and its potential to transform inflammatory heart disease therapy, signaling a major step forward for Cardiol's development pipeline and long-term growth strategy.
----- #3. CRDL Potential Catalyst - Cardiol Therapeutics Secures Broad Patent Protection Through Late 2040.
Cardiol Therapeutics received a U.S. patent allowance covering CardiolRx™ and CRD-38 for treating multiple cardiac conditions, including heart failure, myocarditis, acute pericarditis, and atherosclerosis, through late 2040.
This milestone significantly strengthens the company's intellectual property portfolio in the world's largest pharmaceutical market, complementing granted and pending protections in Europe, Japan, Canada, Australia, and China.
The expanded exclusivity enhances Cardiol's competitive position as it advances late-stage clinical programs and prepares for first-in-human trials of CRD-38. Combined with its U.S. Orphan Drug Designation for pericarditis, this patent fortifies the long-term commercial value of Cardiol's innovative anti-inflammatory and anti-fibrotic heart disease therapies.
----- #4. CRDL Potential Catalyst - Cardiol Therapeutics Announced Phase 2 Topline Results For ARCHER.
Cardiol Therapeutics' Phase 2 ARCHER trial in acute myocarditis showed that CardiolRx™ notably improved a key heart parameter (LV extracellular volume), trending toward statistical significance and accompanied by significant LV mass reduction.
Multiple cardiac MRI endpoints favored CardiolRx™ over placebo, supporting the drug's effectiveness. The therapy demonstrated an excellent safety profile and was well tolerated.
These compelling results provide strong clinical proof of concept, encouraging further development of CardiolRx™ and CRD-38 for heart conditions including myocarditis and heart failure. ----- #5. CRDL Potential Catalyst - Multiple Analyst Targets Point To Triple-Digit Potential Upside!
Take a look at what we found over at TipRanks: 
In case you can't see the fine print, it shares at least 4 Wall Street analysts have provided targets within the last 12 months.
And in each case, their targets are suggesting CRDL to have more than triple-digit upside potential from its chart positioning at close on Monday. ----- (Nasdaq: CRDL) Recap - These 5 Potential Catalysts Lead Our Research
#1. Advancing Therapies That Target Inflammation In The Heart! #2. Promising Advances In Myocarditis Treatment Strengthen Future Outlook. #3. Cardiol Therapeutics Secures Broad Patent Protection Through Late 2040. #4. Cardiol Therapeutics Announced Phase 2 Topline Results For ARCHER. #5. Multiple Analyst Targets Point To Triple-Digit Potential Upside! ----- Consider Starting Your Own Research On (CRDL) Before The Bell Rings
Tomorrow Morning [Company Website] | [Corporate Presentation] We will have all eyes on (CRDL) tomorrow morning. Take a look at (CRDL) before you call it a night. Also, keep a lookout for my morning update. Sincerely, Gary Silver
Managing Editor, Market Crux | 
